Three-month interim data from first-of-its-kind trial demonstrate that the combination of Sculptra and Restylane Lyft or Contour effectively improved the facial aesthetic appearance of patients experiencing medication-driven weight loss with associated facial volume loss1
A six-month extension study is ongoing to capture the combined and sustained effects of these treatments over time
Galderma is well-positioned to support patients’ specific needs in this area, given its unique expertise in dermatology, including aesthetics, and its individualized treatment approach developed in close collaboration with healthcare professionals

ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SWX:GALD) announces positive first results from a trial designed to explore the benefits of Restylane® Lyft™ or Contour™ in combination with Sculptra® in patients with medication-driven weight loss with associated facial volume loss.1 Initial three-month interim data from this first-of-its-kind trial suggest that this treatment combination effectively improved facial aesthetic appearance with high patient satisfaction.1 The results will be presented later today at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California.

Rates of medication-driven weight loss have increased rapidly in recent years and can be associated with facial alterations of variable magnitude.2-4 Patients can find that their skin is less radiant, drier or saggy, and can also observe changes in their facial structure and balance.3,4 Some even find that they appear older than their age.3,4 There are several reasons for these facial alterations including loss of fat, collagen, elastin and essential nutrients such as fatty acids.4